Satellos Bioscience Management
Management criteria checks 0/4
Satellos Bioscience's CEO is Frank Gleeson, appointed in Mar 2018, has a tenure of 6.33 years. total yearly compensation is CA$1.93M, comprised of 20.7% salary and 79.3% bonuses, including company stock and options. directly owns 3.38% of the company’s shares, worth $1.51M. The average tenure of the management team and the board of directors is 1.5 years and 2.6 years respectively.
Key information
Frank Gleeson
Chief executive officer
CA$1.9m
Total compensation
| CEO salary percentage | 20.7% |
| CEO tenure | 6.3yrs |
| CEO ownership | 3.4% |
| Management average tenure | 1.5yrs |
| Board average tenure | 2.6yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -CA$21m |
| Dec 31 2023 | CA$2m | CA$398k | -CA$16m |
| Sep 30 2023 | n/a | n/a | -CA$14m |
| Jun 30 2023 | n/a | n/a | -CA$13m |
| Mar 31 2023 | n/a | n/a | -CA$11m |
| Dec 31 2022 | CA$338k | CA$260k | -CA$11m |
| Sep 30 2022 | n/a | n/a | -CA$9m |
| Jun 30 2022 | n/a | n/a | -CA$18m |
| Mar 31 2022 | n/a | n/a | -CA$17m |
| Dec 31 2021 | CA$1m | CA$226k | -CA$16m |
| Sep 30 2021 | n/a | n/a | -CA$13m |
| Jun 30 2021 | n/a | n/a | -CA$2m |
| Mar 31 2021 | n/a | n/a | -CA$2m |
| Dec 31 2020 | CA$192k | CA$192k | -CA$2m |
| Dec 31 2019 | CA$180k | CA$180k | -CA$2m |
Compensation vs Market: Frank's total compensation ($USD1.42M) is above average for companies of similar size in the US market ($USD702.33K).
Compensation vs Earnings: Frank's compensation has increased whilst the company is unprofitable.
CEO
Frank Gleeson (69 yo)
6.3yrs
Tenure
CA$1,926,547
Compensation
Mr. Francis Gleeson, also known as Frank, B.B.A., M.B.A., is a Co-Founder of Satellos Bioscience Inc. He serves as Chief Executive Officer of Satellos Bioscience Inc. since March 2018. He serves as Directo...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 6.3yrs | CA$1.93m | 3.38% CA$ 1.5m | |
| CFO & Corporate Secretary | less than a year | CA$741.42k | 0.035% CA$ 15.9k | |
| Chief Scientific Officer | 1.5yrs | CA$1.45m | no data | |
| Executive Director | 2.9yrs | CA$216.74k | 1.52% CA$ 679.0k | |
| Head of Corporate Strategy | less than a year | CA$444.38k | no data | |
| Chief Business Officer | less than a year | CA$745.80k | no data | |
| Co-Founder & Chief Discovery Officer | no data | CA$120.00k | 2.73% CA$ 1.2m | |
| Senior Vice President of Finance & Administration | 2.8yrs | no data | 0.071% CA$ 31.7k | |
| Vice President of Corporate Development | no data | no data | no data | |
| Strategic Advisor | 2.9yrs | CA$44.48k | no data | |
| Chief of Staff | no data | no data | no data | |
| Senior Vice President of Clinical Development Operations | less than a year | no data | no data |
1.5yrs
Average Tenure
63yo
Average Age
Experienced Management: MSCL.F's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 12yrs | CA$1.93m | 3.38% CA$ 1.5m | |
| Executive Director | 2.9yrs | CA$216.74k | 1.52% CA$ 679.0k | |
| Independent Director | 1.1yrs | CA$47.41k | 6.04% CA$ 2.7m | |
| Independent Chairman of the Board of Directors | 6yrs | CA$87.84k | 0.23% CA$ 101.0k | |
| Independent Director | 2.9yrs | CA$68.27k | 0.022% CA$ 9.9k | |
| Independent Director | 6.3yrs | no data | 1.31% CA$ 586.8k | |
| Independent Director | 2.6yrs | CA$93.58k | no data | |
| Chair of Clinical Advisory Board & Chief Medical Advisor | less than a year | no data | no data | |
| Member of Clinical Advisory Board | less than a year | no data | no data | |
| Independent Director | 2.6yrs | CA$69.28k | no data | |
| Member of Clinical Advisory Board | less than a year | no data | no data | |
| Member of Clinical Advisory Board | less than a year | no data | no data |
2.6yrs
Average Tenure
62yo
Average Age
Experienced Board: MSCL.F's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.